BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Yang CH, Chen KT, Lin YS, Hsu CY, Ou YC, Tung MC. Improvement of lenvatinib-induced nephrotic syndrome after adaptation to sorafenib in thyroid cancer: A case report. World J Clin Cases 2020; 8(20): 4883-4894 [PMID: 33195657 DOI: 10.12998/wjcc.v8.i20.4883]
URL: https://www.wjgnet.com/2307-8960/full/v8/i20/4883.htm
Number Citing Articles
1
Thaninee Prasoppokakorn, Kessarin Thanapirom, Sombat Treeprasertsuk, Sorabh Kapoor. Nephrotic Syndrome Induced by Lenvatinib Treatment for Hepatocellular CarcinomaCase Reports in Hepatology 2022; 2022: 1 doi: 10.1155/2022/5101856
2
Rossella Di Paola, Ananya De, Anna Capasso, Sofia Giuliana, Roberta Ranieri, Carolina Ruosi, Antonella Sciarra, Caterina Vitagliano, Alessandra F. Perna, Giovambattista Capasso, Mariadelina Simeoni. Impact of Thyroid Cancer Treatment on Renal Function: A Relevant Issue to Be AddressedJournal of Personalized Medicine 2023; 13(5): 813 doi: 10.3390/jpm13050813
3
Tomoya Yokota, Satoshi Hamauchi, Takeshi Kawakami, Kunihiro Fushiki. Lenvatinib rechallenge after failure of lenvatinib and sorafenib in metastatic thyroid cancerInvestigational New Drugs 2024;  doi: 10.1007/s10637-024-01449-9
4
Iodine radioactive/lenvatinibReactions Weekly 2020; 1835(1): 221 doi: 10.1007/s40278-020-87665-8
5
Alice Nervo, Francesca Retta, Alberto Ragni, Alessandro Piovesan, Alberto Mella, Luigi Biancone, Marco Manganaro, Marco Gallo, Emanuela Arvat. Nephrotoxicity in advanced thyroid cancer treated with tyrosine kinase inhibitors: An updateCritical Reviews in Oncology/Hematology 2021; 168: 103533 doi: 10.1016/j.critrevonc.2021.103533
6
Juanjuan Yin, Zexuan Li, Zedong Hao, Zhuanzhuan Yu, Weimin Yu, Guang Yang, Xiaojun Ren. Minimal change disease with papillary thyroid carcinoma: a report of two adult casesBMC Nephrology 2023; 24(1) doi: 10.1186/s12882-023-03252-9